Park et al. antibodies against phospholipid antigens for whose diagnostics we may use some of the methods established for a long time and some of the modern Icatibant methodsthe coagulation method for the dedication of lupus anticoagulant (LA), enzyme-linked imunosorbent assay (ELISA), chemiluminescence analysis (CLIA), multiplex fluorescence circulation immunoassay (MFFIA), fluorescence enzyme immunoassay (EliA), collection immunoassay (LIA), multiline dot assay (MLDA), and thin-layer chromatography (TLC). Summary: Antibodies against phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylinositol, cardiolipin/vimentin complex, and annexin V are currently probably the most analyzed fresh markers. However, these assays have not been standardized until now, both from your laboratory and clinical perspective. With this review we summarize the evidence of the most analyzed aPL markers and their potential medical significance in seronegative APS (SN-APS). Keywords:antiphospholipid syndrome, thrombosis, seronegative APS, lupus anticoagulant, anti-cardiolipin, anti-2-glycoprotein-I, anti-phosphatidylserine/prothrombin, anti-cardiolipin/vimentin, anti-annexin, ELISA, chemiluminescence analysis, multiplex fluorescence circulation immunoassay, fluorescence enzyme immunoassay, collection immunoassay == 1. Intro == Antiphospholipid syndrome (APS), also known as Hughes syndrome, was reported for the first time in 1983 by Dr. Graham Hughes [1]. APS is an autoimmune disease associated with prolonged antiphospholipid antibodies (aPLs). The main target of the aPLs is definitely binding to the phospholipid membranes of platelets with their subsequent activation. However, they also bind to endothelia, monocytes, and neutrophils having a procoagulation effect [2,3]. Antiphospholipid antibodies also interfere with the activation of the Rabbit Polyclonal to NEIL1 match. All this may consequently result in the development of thrombosis [4]. APS may be main and also secondary. Primary APS is definitely a disorder in which the patient has no additional autoimmune disease. Secondary APS happens in connection with another autoimmune disease: systemic lupus erythematosus (SLE) [5,6,7]. Prevalence of aPLs Icatibant in the population is definitely approximately 15%, but only a minor part evolves APS [8]. However, APS is considered to become the most common cause of acquired thrombophilia despite this truth. Clinical manifestations of APS are very variable. Venous thromboses may be manifested by phlebothrombosis of the lower or top limbs, or by pulmonary embolism. Myocardial infarction or cerebrovascular accident is usually a result of arterial thromboses. In the group of pregnancy-related complications, APS is frequently a cause of preeclampsia, miscarriages, premature labor, Icatibant growth retardation of the fetus due to an insufficient placenta, or death of the fetus. Migraine, immune thrombocytopenia, transient ischemic assault, livedo reticularis, autoimmune hemolytic anemia, and many others were observed as additional non-criteria medical manifestations of APS [9]. Progression of catastrophic antiphospholipid syndrome (CAPS) happens in approximately 1% of individuals with APS, whereby the patient is definitely affected by thromboses mostly in small vessels, leading to multiorgan failure. CAPS is definitely a very severe condition with high mortality [10,11]. Criteria for APS according to the Sydney classification are very purely defined; at least one medical and at least one laboratory criterion must be met. Clinical criteria of APS include the event of arterial or venous thromboses and reproduction deficits [12,13]. Up to 1020% of recurrent reproduction losses and up to 20% of cerebrovascular incidents in individuals below the age of 50 are caused by APS [14,15]. Laboratory criteria include positivity of at least one antibody of the anti-cardiolipin (aCL) IgG and IgM, anti-2-glycoprotein-I (anti-2GPI) IgG and IgM, and the lupus anticoagulant (LA) type [16]. In order to meet the laboratory criteria, the aPLs must be repeatedly positive in an interval of 12 weeks [17]. It is evaluated whether this is solitary, double, or triple positivity, since individuals with triple positivity have the highest risk of thromboses and recurrent miscarriages [18,19,20]. It is required to avoid laboratory examination of APS during ongoing illness due to false positivity of the aPLs [21]. == 2. Antiphospholipid Antibodies == There is a wide range of antiphospholipid antibodies that interact with negatively charged phospholipid surfaces of many cells and cells by various mechanisms. These aPLs, explained Icatibant onFigure 1, include APS criteria antibodies of the lupus anticoagulant, anti-cardiolipin, anti-2-glycoprotein-I type, and APS non-criteria antibodies of the anti-2-glycoprotein-I website I (anti-DI), anti-annexin V, anti-annexin II, anti-prothrombin (anti-PT), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-cardiolipin/vimentin (aCL/Vim), Icatibant anti-protein S/protein C (anti-PS/Personal computer) type, as well as others. == Figure.